Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akebia, Aldeyra,  Alumis, Amytrx, Astrazeneca, Biontech, Bioxcel, Delsitech, Haemalogix, Intrabio, Jacobio, Junshi, Nanoviricides, Oncoc4, Plus, Renovorx, Urica.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzamend, Aptorum, Biocity, Compugen, Horizon, Hyloris, Ideaya, Inhibikase, Inmed, Invivyd, Jasper, Madrigal, Memo, Palleon, Reviva, Roivant, Seelos, Sellas, Tvardi, Vaxxinity.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adicet, Aldeyra, Aveo, Bavarian Nordic, Biorestorative, Bioxytran, Black Diamond, Cassava, Edgewise, Eli Lilly, Freya, Harpoon, Idorsia, Inozyme, Lobe, Meiragtx, Minervax, Nkarta, Regulus, Sanofi.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alx, Invivyd, Pharvaris.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Agios, Alligator, Avalo, Canbridge, Fibrogen, Freeline, Janssen, Lexicon, Pfizer, Portage, Rallybio, Sanofi, Savara, Sorrento, Takeda.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Amylyx, Astrazeneca, Boehringer Ingelheim, Erasca, Gilead, Intercept, Janssen, Leo, Lianbio, Moderna, Molecure, Pfizer, Sarepta, Zealand.

The U.S. FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend COVID-19 vaccines for the 2023-2024 vaccination campaign be monovalent vaccines that target the XBB variants, currently the most prominent variants of the SARS-CoV-2 virus.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Bloomsbury, Lantern, Merck & Co., Neobiosis, Pharmala, Phathom.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Acadia, ADC, Astellas, Beigene, Crispr, Disc, Editas, Faron, Genmab, Gritstone, Immunogen, Keros, Nuvox, Roche, Ryvu, Servier, Vertex, Vor, Wugen.